GLUC · CIK 0001420108
GLUCOSE HEALTH, INC.
Annual figures as reported, FY2009–FY2016. Ratios and growth rates derived on-page.
Medicinal Chemicals & Botanical Products
Company profile
Revenue
$313K
▲ +7232.1% vs FY2015
Net income
−$410K
▼ −54.3% vs FY2015
Operating cash flow
−$39K
▲ +66.1% vs FY2015
Diluted EPS
−$0.15
▼ −7.1% vs FY2015
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Sep ’17 quarter
$24K
▲ +1027.2% vs Sep ’16
Net income — Sep ’17 quarter
$19K
▲ +111.7% vs Sep ’16
Revenue — trailing 12 months
$88K
▼ −70.6% vs Sep ’16
Diluted EPS — trailing 12 months
−$0.05
▲ +54.5% vs Sep ’16
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Sep ’17 | $24K | 1027.2% | 96.7% | $19K | 78.9% | $0.00 |
| Jun ’17 | $34K | −88.5% | 99.2% | $49K | 144.7% | $0.01 |
| Mar ’17 | $15K | 12492.5% | 3.1% | −$29K | −192.0% | −$0.01 |
| Dec ’16 | $15K | 826.2% | 2.5% | −$133K | −875.5% | −$0.05 |
| Sep ’16 | $2K | 2.7% | −124.4% | −$161K | −7621.8% | −$0.06 |
| Jun ’16 | $296K | 53488.6% | 7.2% | −$87K | −29.5% | −$0.03 |
| Mar ’16 | $120 | 380.0% | 50.0% | −$29K | −24385.8% | −$0.01 |
| Dec ’15 | $2K | — | 3.4% | −$47K | −2853.5% | −$0.01 |
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Gross marginOperating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedRevenue CAGR
+1018.2%
3y
Share count change (split-adjusted)
+3752.2%
5y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Op. margin | Net margin | ROE | ROA | Current ratio |
|---|---|---|---|---|---|---|
| FY2016 | 6.1% | −27.7% | −131.0% | — | −1238.3% | 0.06× |
| FY2015 | 9.3% | −3655.7% | −6228.1% | — | −1726.9% | 0.04× |
| FY2014 | −756.7% | −19905.7% | −24439.9% | — | −1520.3% | 0.13× |
| FY2013 | −933.5% | −566644.6% | −651404.5% | — | −5702.0% | 0.11× |
| FY2012 | — | — | — | −1797.6% | −192.2% | 0.01× |
| FY2011 | — | — | — | — | −384.8% | 0.06× |
| FY2010 | −39.4% | −25554.8% | −26298.5% | — | −720.7% | 0.13× |
| FY2009 | — | — | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2016 | $313K | $19K | −$87K | −$410K | −$0.15 | −$39K | — | $33K | $529K | −$495K | $21K | — |
| FY2015 | $4K | $397 | −$156K | −$266K | −$0.14 | −$116K | — | $15K | $403K | −$388K | $2K | — |
| FY2014 | $3K | −$21K | −$545K | −$669K | −$0.99 | −$135K | — | $44K | $325K | −$281K | $5K | — |
| FY2013 | $224 | −$2K | −$1.3M | −$1.5M | −$4.91 | −$132K | — | $26K | $223K | −$198K | $711 | — |
| FY2012 | — | — | −$361K | −$399K | −$2.50 | −$84K | — | $208K | $185K | $22K | $1K | — |
| FY2011 | — | — | −$889K | −$899K | −$10.00 | −$23K | — | $234K | $420K | −$310K | $4K | — |
| FY2010 | $2K | −$947 | −$615K | −$633K | −$15.00 | −$110K | — | $88K | $682K | −$595K | $33 | — |
| FY2009 | — | — | — | — | — | — | — | — | — | −$301K | $4 | — |
Latest filings
the most recent regulatory filingsDSEC filing2026-02-04 ↗DSEC filing2025-12-05 ↗D/ASEC filing2024-01-19 ↗DSEC filing2023-12-07 ↗RWSEC filing2023-06-28 ↗S-1/ASecurities registration2023-01-09 ↗S-1/ASecurities registration2022-09-06 ↗S-1/ASecurities registration2022-08-05 ↗S-1Securities registration2022-06-01 ↗DSEC filing2021-03-09 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.